Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationDepreciation & Amortization (IS)EBIATLeasesLong-Term Debt RepaymentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables RefundsShares IssuedShares RepurchasedShort-Term Debt issuancesWages, Salaries and Other
Ratios

Amphastar Pharmaceuticals (AMPH) EBIAT (2016 - 2025)

Historic EBIAT for Amphastar Pharmaceuticals (AMPH) over the last 13 years, with Q3 2025 value amounting to $17.3 million.

  • Amphastar Pharmaceuticals' EBIAT fell 5708.53% to $17.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $111.6 million, marking a year-over-year decrease of 2922.42%. This contributed to the annual value of $159.5 million for FY2024, which is 1597.59% up from last year.
  • According to the latest figures from Q3 2025, Amphastar Pharmaceuticals' EBIAT is $17.3 million, which was down 5708.53% from $31.0 million recorded in Q2 2025.
  • Amphastar Pharmaceuticals' 5-year EBIAT high stood at $49.2 million for Q3 2023, and its period low was $5.0 million during Q1 2021.
  • Its 5-year average for EBIAT is $27.7 million, with a median of $26.1 million in 2023.
  • As far as peak fluctuations go, Amphastar Pharmaceuticals' EBIAT skyrocketed by 70335.9% in 2021, and later crashed by 5708.53% in 2025.
  • Quarter analysis of 5 years shows Amphastar Pharmaceuticals' EBIAT stood at $19.8 million in 2021, then surged by 71.62% to $33.9 million in 2022, then increased by 6.65% to $36.2 million in 2023, then grew by 4.97% to $38.0 million in 2024, then crashed by 54.3% to $17.3 million in 2025.
  • Its EBIAT was $17.3 million in Q3 2025, compared to $31.0 million in Q2 2025 and $25.3 million in Q1 2025.